The Food and Drug Administration rejected a bid from Elon Musk's human brain chips startup Neuralink to start human trials, according to Reuters.
Share:
More In Science
Modified Mosquitoes to Fight Illness in Florida Keys
Genetically modified mosquitoes are being released in the Florida Keys in an effort to combat persistent insect-borne diseases such as Dengue fever and the Zika virus.
Disneyland Opening Highlights California's COVID Turnaround
Disneyland has reopened after a 13-month closure. The iconic theme park in Southern California that was closed under the state's strict virus rules swung open its gates Friday and some visitors came in cheering and screaming with happiness.
Need2Know: Israel Stampede, Economic Rewiring & Love, Hate, Ate
An overnight stampede in Israel kills dozens, a look at the COVID disaster in Latin America, the economic repositioning in America, a new shortage to report and did people really answer the phone without Caller ID?
Satellites Show World's Glaciers Melting Faster Than Ever
A new study of the world's 220,000 mountain glaciers finds that they are melting faster now than in the early 2000s.
China Launches Main Part of Its 1st Permanent Space Station
China has launched the main module of its first permanent space station that will host astronauts long term.
Need2Know: Biden's Speech, License Deadline & Grocery Wars
The headlines from President Biden's first speech to Congress, plus why he's got reason to be sounding optimistic about the state of the pandemic. And would you let a Walmart worker stock your fridge?
Need2Know: Mask Rules, Biden Address & Malaria Breakthrough
Jill and Carlo discuss the CDC's updated mask guidance, a deeper dive into the catastrophe in India, what POTUS will pitch to Congress, and the biggest public health breakthrough of the decade that you haven't heard about.
India Grieves 200,000 Dead With Many More Probably Uncounted
India’s official death toll has passed 200,000, but the true number is likely far higher.
Psychedelics Medicine Company MindMed Makes Nasdaq Debut
MindMed CEO J.R. Rahn spoke to Cheddar about the psychedelic mental health therapy company taking the big step forward going public on the Nasdaq exchange.
